Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents

BACKGROUND AND PURPOSE: Atomoxetine is a selective noradrenaline reuptake inhibitor, recently approved for the treatment of attention-deficit/hyperactivity disorder. So far, atomoxetine has been shown to be well tolerated, and cardiovascular effects were found to be negligible. However, two independ...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Scherer, Daniel, Hassel, David, Bloehs, Ramona, Zitron, Edgar, von Löwenstern, Katharina, Seyler, Claudia, Thomas, Dierk, Konrad, Franziska, Bürgers, Heiner F, Seemann, Gunnar, Rottbauer, Wolfgang, Katus, Hugo A, Karle, Christoph A, Scholz, Eberhard P
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2009
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2697834/
https://ncbi.nlm.nih.gov/pubmed/19154426
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2008.00018.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia